|
Common Stock (Narrative) (Details) (USD $)
|
0 Months Ended | 1 Months Ended | 12 Months Ended | 0 Months Ended | 0 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Mar. 31, 2011
|
Mar. 11, 2011
|
Feb. 28, 2011
|
Feb. 15, 2011
|
Jan. 19, 2011
|
Jun. 30, 2010
|
Apr. 20, 2010
|
Oct. 23, 2009
|
Sep. 21, 2009
|
Sep. 04, 2009
|
Jun. 09, 2009
|
Jun. 05, 2009
|
Jun. 30, 2008
|
Jun. 02, 2008
|
May 30, 2008
|
Mar. 20, 2008
|
Dec. 27, 2007
|
Dec. 18, 2007
|
Sep. 27, 2007
|
Jul. 23, 2007
|
Apr. 18, 2007
|
Dec. 19, 2006
|
Nov. 19, 2006
|
Oct. 09, 2006
|
May 13, 2006
|
Apr. 12, 2006
|
Feb. 22, 2006
|
Dec. 27, 2005
|
Dec. 02, 2005
|
Aug. 08, 2005
|
Oct. 29, 2004
|
May 10, 2001
|
Oct. 31, 2011
|
Sep. 30, 2011
|
Jan. 19, 2011
|
Dec. 31, 2010
|
Nov. 30, 2010
|
May 31, 2010
|
Apr. 30, 2010
|
Mar. 31, 2010
|
Sep. 21, 2009
|
Jul. 31, 2003
|
Dec. 31, 2011
|
Jun. 30, 2012
|
Aug. 10, 2001
Director [Member]
|
Aug. 10, 2001
Rexgene [Member]
|
Oct. 10, 2001
Individual Investors [Member]
|
Aug. 10, 2001
Individual Investors [Member]
|
Oct. 10, 2001
Chong Kun Dang Pharmaceutical Corp [Member]
|
Oct. 10, 2001
Chong Kun Dang Pharmaceutical Corp Issuance Two [Member]
|
Aug. 20, 2003
KT&G Corporation [Member]
|
May 13, 2005
Corporate Road Show Com Inc. [Member]
|
Oct. 03, 2005
W. Rosenstadt And Steve Sanders [Member]
|
Oct. 23, 2009
Second Issuance [Member]
|
Jun. 05, 2009
Series I Warrants [Member]
|
Jun. 05, 2009
Series II Warrants [Member]
|
Jun. 05, 2009
Series III Warrants [Member]
|
Mar. 31, 2011
Warrants To Institutional Investors [Member]
|
Jun. 30, 2010
Warrants To Placement Agent [Member]
|
Dec. 18, 2007
Warrants To Placement Agent [Member]
|
|
| Shares issued | 8,333,333 | 2,334,515 | 6,666,667 | 6,072,383 | 3,102,837 | 2,857,143 | 642,858 | 4,857,159 | 3,850,000 | 650,000 | 4,175,000 | 3,600,000 | 2,334,515 | 3,102,837 | 1,208,332 | 958,334 | 400,000 | 360,000 | 400,000 | 200,000 | 500,000 | 500,000 | 7,000 | |||||||||||||||||||||||||||||||||||||
| Value of shares issued | $ 1 | $ 3,950,000 | $ 3,500,000 | $ 1,450,000 | $ 550,000 | $ 479,991 | $ 1,080,000 | $ 479,991 | $ 479,985 | $ 2,000,000 | $ 21,877 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Shares transferred to officers and directors | 800,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Shares transferred to a voting trust | 1,268,332 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Value of exercised of stock options | 12,000 | 6,000 | 86,000 | 3,600 | 12,000 | 12,000 | 7,200 | 18,000 | 15,600 | 12,000 | 14,400 | 6,000 | 1,800 | 2,400 | 3,409 | 1,200 | 9,600 | 1,800 | 19,200 | 22,040 | 21,240 | |||||||||||||||||||||||||||||||||||||||
| Shares issued for options exercised | 50,000 | 25,000 | 107,500 | 15,000 | 10,000 | 50,000 | 30,000 | 75,000 | 19,500 | 15,000 | 18,000 | 25,000 | 7,500 | 10,000 | 14,205 | 5,000 | 40,000 | 1,500 | 80,000 | 28,000 | 48,000 | |||||||||||||||||||||||||||||||||||||||
| Pre-reverse stock split shares | 289,780,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Post-reverse stock split shares | 2,897,802 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance price per share | $ 1.20 | $ 1.69 | $ 1.50 | $ 0.82 | $ 1.13 | $ 1.05 | $ 1.05 | $ 1.40 | $ 1.40 | $ 1.00 | $ 2.00 | $ 2.00 | $ 0.82 | $ 1.05 | $ 1.25 | $ 1.50 | ||||||||||||||||||||||||||||||||||||||||||||
| Cash paid in exchange for legal services | 7,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Convertable note principal amount | 3,850,000 | 1,300,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Purchase of treasury stock | 28,410 | 28,410 | 28,410 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Gross proceeds from issuance | 10,000,000 | 3,926,397 | 10,000,000 | 5,000,000 | 3,371,340 | 3,000,000 | 900,001 | 6,800,023 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Exercise price at future date | $ 1.50 | $ 1.90 | $ 1.00 | $ 1.80 | $ 1.80 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Private placement closing costs | 139,675 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Number of warrants, Issued | 3,333,333 | 2,000,000 | 2,125,334 | 862,246 | 3,541,666 | 569,502 | 2,222,222 | 1,866,666 | 1,555,555 | 200,000 | 107,144 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Proceeds allocated to financing expense | 97,667 | 180,080 | 101,693 | 122,257 | 138,326 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance cost incurred | 706,124 | 23,603 | 681,773 | 351,928 | 128,659 | 289,090 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fair value | 11,054,427 | 1,800,800 | 422,300 | 868,725 | 328,338 | 476,200 | 2,826,666 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash paid for warrants exercised | $ 102,857 | $ 215,104 | $ 1,966,375 | $ 1,297,001 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Shares issued for warrants exercised | 124,917 | 209,042 | 126,195 | 247,491 | 547,674 | 1,595,825 | 1,197,001 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Number of warrants, Exercised | 530,900 | 936,883 | 890,051 | (333,959) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Warrants issued included in closing costs | 208,333 | 245,932 | 142,857 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock Issued During Period, Shares Issued in Accordance to the anti-dilution provision | 1,833,341 | 2,018,143 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||